HOLON, Israel, Nov. 6, 2017 /PRNewswire/ -- Compugen Ltd.
(NASDAQ: CGEN), a leader in predictive discovery and development of
first-in-class therapeutics for cancer immunotherapy, today
announced that it is advancing COM902, its lead anti-TIGIT
antibody, into manufacturing in anticipation of filing an
investigational new drug (IND) application in 2019. As part of
these activities, Compugen has entered into a process development
and manufacturing service agreement with Bayer
HealthCare LLC (Bayer) to produce COM902 for future use in clinical
trials. This program follows COM701, an anti-PVRIG antibody, for
which the submission of an IND application is anticipated towards
the end of the first quarter of 2018.
"As a company with long-standing advanced biologics
manufacturing experience and a commitment to advancing novel cancer
therapies, we collaborate with a few select partners to develop and
manufacture their own pipeline programs," said Sunil Gupta, Vice President of Biological
Development at Bayer. "Compugen has been a valued partner for Bayer
and we look forward to working with the Compugen team to produce
and prepare COM902 for clinical testing."
"The development of COM902 will allow us to address various drug
combination possibilities of COM701, which can potentially offer
significant therapeutic value for cancer patients. We are delighted
to enter this service agreement with Bayer for the manufacture of
COM902, and to benefit from their expertise and the quality of
their cGMP operations," said Anat
Cohen-Dayag, PhD, President and CEO of Compugen. "We are
working towards filing an IND for COM902 in 2019, making it
available for our clinical testing in combination with COM701 and
enabling us to more fully explore the commercial value of
COM701."
About Compugen
Compugen is a therapeutic discovery and development company
utilizing its broadly applicable predictive discovery
infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel, with R&D facilities in
both Israel and South San Francisco, CA. Compugen's shares are
listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker
symbol CGEN.
For additional information, please visit Compugen's corporate
website at www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," and "intends," and describe opinions about possible
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Among these risks:
Compugen's business model is substantially dependent on entering
into collaboration agreements with third parties, Compugen may not
be successful in generating adequate revenues or commercializing
aspects of its business model. Moreover, the development and
commercialization of therapeutic candidates involve many inherent
risks, including failure to progress to clinical trials or, if they
progress to or enter clinical trials, failure to receive regulatory
approval. These and other factors are more fully discussed in the
"Risk Factors" section of Compugen's most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission
(SEC) as well as other documents that may be subsequently filed by
Compugen from time-to-time with the SEC. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugen-to-initiate-manufacturing-of-com902-its-lead-anti-tigit-monoclonal-antibody-300549878.html
SOURCE Compugen Ltd.